|
1
|
Ambrosetti MC, Colato C, Dardano A,
Monzani F and Ferdeghini M: Radioiodine ablation: when and how. Q J
Nucl Med Mol Imaging. 53:473–481. 2009.PubMed/NCBI
|
|
2
|
Hannallah J, Rose J and Guerrero MA:
Comprehensive literature review: recent advances in diagnosing and
managing patients with poorly differentiated thyroid carcinoma. Int
J Endocrinol. 2013:3174872013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dar AC and Shokat KM: The evolution of
protein kinase inhibitors from antagonists to agonists of cellular
signaling. Annu Rev Biochem. 80:769–795. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gild ML, Bullock M, Robinson BG and
Clifton-Bligh R: Multikinase inhibitors: a new option for the
treatment of thyroid cancer. Nat Rev Endocrinol. 7:617–624. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Antonelli A, Fallahi P, Ferrari SM, et al:
Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed
Pharmacother. 62:559–563. 2008. View Article : Google Scholar
|
|
6
|
Nikiforov YE: Thyroid carcinoma: molecular
pathways and therapeutic targets. Mod Pathol. 21:S37–S43. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saji M and Ringel MD: The PI3K-Akt-mTOR
pathway in initiation and progression of thyroid tumors. Mol Cell
Endocrinol. 32:20–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duntas LH and Bernardini R: Sorafenib:
rays of hope in thyroid cancer. Thyroid. 2:1351–1358. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fallahi P, Ferrari SM, Santini F, et al:
Sorafenib and thyroid cancer. BioDrugs. 27:615–628. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chai H, Luo AZ, Weerasinghe P and Brown
RE: Sorafenib downregulates ERK/Akt and STAT3 survival pathways and
induces apoptosis in a human neuroblastoma cell line. Int J Clin
Exp Pathol. 3:408–415. 2010.PubMed/NCBI
|
|
12
|
Carlo-Stella C, Locatelli SL, Giacomini A,
et al: Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK
and AKT pathways in tumor and vascular cells. PLoS One.
8:e616032013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nguyen TK, Jordan N, Friedberg J, Fisher
RI, Dent P and Grant S: Inhibition of MEK/ERK1/2 sensitizes
lymphoma cells to sorafenib-induced apoptosis. Leuk Res.
34:379–386. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rose A, Grandoch M, vom Dorp F, Rübben H,
Rosenkranz A, Fischer JW and Weber AA: Stimulatory effects of the
multikinase inhibitor sorafenib on human bladder cancer cells. Br J
Pharmacol. 160:1690–1698. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gedaly R, Angulo P, Hundley J, Daily MF,
Chen C and Evers BM: PKI-587 and sorafenib targeting PI3K/AKT/mTOR
and Ras/Raf/MAPK pathways synergistically inhibit HCC cell
proliferation. J Surg Res. 176:542–548. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fremin C and Meloche S: From basic
research to clinical development of MEK1/2 inhibitors for cancer
therapy. J Hematol Oncol. 3:Feb 11–2010. View Article : Google Scholar
|
|
17
|
Glassmann A, Reichmann K, Scheffler B,
Glas M, Veit N and Probstmeier R: Pharmacological targeting of the
constitutively activated MEK/MAPK-dependent signaling pathway in
glioma cells inhibits cell proliferation and migration. Int J
Oncol. 39:1567–1575. 2011.PubMed/NCBI
|
|
18
|
Mendoza MC, Er EE and Blenis J: The
Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends
Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kandil E, Tsumagari K, Ma J, et al:
Synergistic inhibition of thyroid cancer by suppressing
MAPK/PI3K/AKT pathways. J Surg Res. 184:898–906. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hong SK, Jeong JH, Chan AM and Park JI:
AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation
in prostate cancer cells in response to androgen depletion. Exp
Cell Res. 319:1732–1743. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Niba ET, Nagaya H, Kanno T, et al:
Crosstalk between PI3 kinase/PDK1/Akt/Rac1 and Ras/Raf/MEK/ERK
pathways downstream PDGF receptor. Cell Physiol Biochem.
31:905–913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang CC, Cirit M and Haugh JM:
PI3K-dependent cross-talk interactions converge with Ras as
quantifiable inputs integrated by Erk. Mol Syst Biol.
5:2462009.PubMed/NCBI
|
|
23
|
Meloche S and Pouysségur J: The ERK1/2
mitogen-activated protein kinase pathway as a master regulator of
the G1- to S-phase transition. Oncogene. 26:3227–3239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Whalen AM, Galasinski SC, Shapiro PS,
Nahreini TS and Ahn NG: Megakaryocytic differentiation induced by
constitutive activation of mitogen-activated protein kinase kinase.
Mol Cell Biol. 17:1947–1958. 1997.PubMed/NCBI
|
|
25
|
Chen H, Zhu G, Li Y, et al: Extracellular
signal-regulated kinase signaling pathway regulates breast cancer
cell migration by maintaining slug expression. Cancer Res.
69:9228–9235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang C, Jacobson K and Schaller MD: MAP
kinases and cell migration. J Cell Sci. 117:4619–4628. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Knight ZA, Lin H and Shokat KM: Targeting
the cancer kinome through polypharmacology. Nat Rev Cancer.
10:130–137. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin N, Jiang T, Rosen DM, Nelkin BD and
Ball DW: Dual inhibition of mitogen-activated protein kinase kinase
and mammalian target of rapamycin in differentiated and anaplastic
thyroid cancer. J Clin Endocrinol Metab. 94:4107–4112. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu D and Xing M: Potent inhibition of
thyroid cancer cells by the MEK inhibitor PD0325901 and its
potentiation by suppression of the PI3K and NF-kappaB pathways.
Thyroid. 18:853–864. 2008. View Article : Google Scholar : PubMed/NCBI
|
